Phytochemical investigation of the ethyl acetate fraction from aerial parts of Aster glehni afforded five new caffeoylglycoside derivatives, namely 6ʹ-O-caffeoyl-(6S,9R)-roseoside (1) , 6ʹ-O-caffeoylampelopsisionoside (2), 6ʹ-O-caffeoylsonchuinoside C (3), 6ʹ-O-caffeoyldihydrosyringin (4), and (2E)-...
Phytochemical investigation of the ethyl acetate fraction from aerial parts of Aster glehni afforded five new caffeoylglycoside derivatives, namely 6ʹ-O-caffeoyl-(6S,9R)-roseoside (1) , 6ʹ-O-caffeoylampelopsisionoside (2), 6ʹ-O-caffeoylsonchuinoside C (3), 6ʹ-O-caffeoyldihydrosyringin (4), and (2E)-2-methyl-but-2-ene-1,4-diol-6ʹ-O-caffeoyl-1-O-β-glucopyranoside (glehnoside, 5), together with thirteen known compounds. The structures of these compounds were determined by spectroscopic analyses. The absolute stereochemistry of the 6ʹ-O-caffeoylsonchuinoside C (3) was established with the help of spectroscopic analyses, enzyme hydrolysis, Mosher’s method, and in comparison with literature data. All isolated substances were determined for their antioxidant activities using three different cell-free assay systems. Among them, 4,5-O-dicaffeoylquinic acid methyl ester (12) showed the most potent antioxidant activities, which were found to be more potent than those of resveratrol, ascorbic acid, and trolox used as positive controls. Five new compounds showed moderate antioxidant activities. Also, in the search for xanthine oxidase inhibitors as anti-gout agents from natural products, all isolated substances were determined for their inhibitory activities on uric acid production by the xanthine/xanthine oxidase system. Among them, 4,5-O-dicaffeoylquinic acid methyl ester (12) showed the most potent inhibitory activity with an IC50 value of 2.6 ± 0.1 μM, which was comparable to that of allopurinol used as a positive control. Furthermore, hypouricemic effects of AGEF were assessed by measuring serum uric acid levels 3 h after potassium oxonate treatment (250 mg/kg, i.p.) to induce hyperuricemia in rats. When administered orally once a day at doses of 50, 100 and 300 mg/kg for 7 days (6-day pretreatment + 1-hr posttreatment), AGEF reduced the serum uric acid level elevated by potassium oxonate from the normal control level by 15.4, 39.8 and 32.3%, respectively, with significance only at the higher two doses, compared with the vehicle-treated hyperuricemic group. The results suggest that AGEF has potential to be a new source of agents for the prevention and/or treatment of hyperuricemia and gout.
Phytochemical investigation of the ethyl acetate fraction from aerial parts of Aster glehni afforded five new caffeoylglycoside derivatives, namely 6ʹ-O-caffeoyl-(6S,9R)-roseoside (1) , 6ʹ-O-caffeoylampelopsisionoside (2), 6ʹ-O-caffeoylsonchuinoside C (3), 6ʹ-O-caffeoyldihydrosyringin (4), and (2E)-2-methyl-but-2-ene-1,4-diol-6ʹ-O-caffeoyl-1-O-β-glucopyranoside (glehnoside, 5), together with thirteen known compounds. The structures of these compounds were determined by spectroscopic analyses. The absolute stereochemistry of the 6ʹ-O-caffeoylsonchuinoside C (3) was established with the help of spectroscopic analyses, enzyme hydrolysis, Mosher’s method, and in comparison with literature data. All isolated substances were determined for their antioxidant activities using three different cell-free assay systems. Among them, 4,5-O-dicaffeoylquinic acid methyl ester (12) showed the most potent antioxidant activities, which were found to be more potent than those of resveratrol, ascorbic acid, and trolox used as positive controls. Five new compounds showed moderate antioxidant activities. Also, in the search for xanthine oxidase inhibitors as anti-gout agents from natural products, all isolated substances were determined for their inhibitory activities on uric acid production by the xanthine/xanthine oxidase system. Among them, 4,5-O-dicaffeoylquinic acid methyl ester (12) showed the most potent inhibitory activity with an IC50 value of 2.6 ± 0.1 μM, which was comparable to that of allopurinol used as a positive control. Furthermore, hypouricemic effects of AGEF were assessed by measuring serum uric acid levels 3 h after potassium oxonate treatment (250 mg/kg, i.p.) to induce hyperuricemia in rats. When administered orally once a day at doses of 50, 100 and 300 mg/kg for 7 days (6-day pretreatment + 1-hr posttreatment), AGEF reduced the serum uric acid level elevated by potassium oxonate from the normal control level by 15.4, 39.8 and 32.3%, respectively, with significance only at the higher two doses, compared with the vehicle-treated hyperuricemic group. The results suggest that AGEF has potential to be a new source of agents for the prevention and/or treatment of hyperuricemia and gout.
주제어
#Aster glehni Compositae Caffeoylglycoside derivatives Quinic acid derivatives Antioxidant activity Hyperuricemia Uric acid Xanthine oxidase
※ AI-Helper는 부적절한 답변을 할 수 있습니다.